Biotechnology

Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2024-06-12 08:00 4282

Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE

SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) ofChina'...

2024-06-11 11:25 4483

India Breakthrough: Bio Regenerative Precision Medicine Seminar Held in Hyderabad

HYDERABAD, India, June 10, 2024 /PRNewswire/ -- The Bio Regenerative Precision Medicine Seminar, held fromMay 18-20, 2024, at Le Méridien in Hyderabad, was a watershed moment inIndia's cell treatment journey. Prof. Dr Mike Chan, Chairman and Founder of European Wellness Biomedical Group (EWBG)...

2024-06-10 15:40 3409

deCODE genetics: The rate, nature and transmission of mitochondrial DNA mutations in humans

A new study from deCODE genetics uses pedigrees and sequence data from 64,806 Icelanders to shed light on the rate and nature of mutations in mitochondrial DNA (mtDNA) and the peculiar dynamics of its maternal transmission REYKJAVIK, Iceland, June 7, 2024 /PRNewswire/ -- In a paper published toda...

2024-06-07 23:00 4031

IONETIX Produces First Batch of Actinium-225

LANSING, Mich., June 7, 2024 /PRNewswire/ -- IONETIX, a leading cyclotron technology innovator, isotope producer, and radiopharmaceutical manufacturer, announced today the successful production of Actinium-225 ("Ac-225") at its isotope manufacturing facility located inLansing, Michigan. This fir...

2024-06-07 20:27 2485

Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024

New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection BRII-179 as add-on therapy induces functional antibody responses and contributes toimproved sustained HBsAg loss in PEG-IFNa-t...

2024-06-07 19:00 4356

Clinical Data of First-in-class HBV-specificTCR T Cell Therapy (SCG101) Presented at ESAL Congress Showing Improved Overall Survival in HBV-related Hepatocellular Carcinoma

SINGAPORE, June 7, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced that clinical data from its first-in-class autologous hepatitis B virus (HBV)-specific...

2024-06-07 16:51 3698

MLB Announces IND Approval by US FDA to Initiate Phase 1 Trial of TML-6, a New Era Multi-Target Drug for the Treatment of Alzheimer's Disease

TAINAN, June 7, 2024 /PRNewswire/ -- MLB (Merry Life Biomedical Company, Ltd., Taiwan: https://www.tmlbio.com/ ), a biomedical company, announced that the U.S. Food and Drug Administration (FDA) has approved IND application forTML-6, an novel drug to treat Alzheimer's dis...

2024-06-07 15:00 3057

Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products

SUZHOU, China, June 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of the Company, entered into a research and collaboration agreement (the "Collaboration Agreement") with ArriVen...

2024-06-06 10:21 3321

Tianlong Promotes Environmental Sustainability and Hygiene Monitoring with its Biolum Portable ATP Hygiene Monitoring System Series

XI'AN, China, June 5, 2024 /PRNewswire/ -- In honor of World Environment Day on 5 June,Tianlong , an innovative R&D company specializing in molecular diagnostic products, demonstrates its dedication to environmental sustainability and cleanliness through the introduction o...

2024-06-05 14:13 4197

Xinhua Silk Road: Enterprise in E. China's Shandong Weihai dedicated to American ginseng products dev't

BEIJING, June 5, 2024 /PRNewswire/ -- In the workshops of Shandong Yiyang Biotechnology Co., Ltd. (Yiyang Biotechnology) in Weihai City, eastChina's Shandong Province, four new intelligent production lines recently were busy producing various types of American ginseng products, which were later s...

2024-06-05 11:16 3669

Zymo Research Unveils PureRec DSN: The Most Selective Duplex-Specific Nuclease

IRVINE, Calif., June 4, 2024 /PRNewswire/ -- Zymo Research, a leader in biotechnological advancement has launched a new nuclease calledPureRec Duplex-Specific Nuclease (DSN) that selectively digests double stranded DNA (dsDNA). This new PureRec DSN promises unparalleled specificity in targeting ...

2024-06-04 21:00 1778

Angel Yeast Partners with BakeMark Launching Multiple Product Lines at Bakery China 2024

SHANGHAI, June 4, 2024 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, joined hands with BakeMark to unveil a variety of product lines under the name BakeMark By Angel at Bakery China 2024, the 26th edition of the largest exhibition in...

2024-06-04 19:00 23828

AmpleLogic Launches Advanced aPaaS for Life Sciences with 14 Ready-to-Use Applications

HYDERABAD, India, June 4, 2024 /PRNewswire/ -- AmpleLogic, a leading provider of GAMP solutions, announces the launch of its revolutionaryApplication Platform as a Service (aPaaS) designed specifically for the life sciences sector. This ...

2024-06-04 13:30 2008

RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88

YANTAI, China, June 4, 2024 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center Phase I/II study evaluating RC8...

2024-06-04 09:38 2587

Built by Nature Prize Awards €500,000 to Biobased Construction Innovators

AMSTERDAM, June 4, 2024 /PRNewswire/ -- Built by Nature is pleased to announce the winners of its inaugural global Prize to stimulate uptake of innovative biobased construction materials, with a €250,000 first prize awarded toSingapore-based company Widuz for its bamboo product solutions. Widu...

2024-06-04 08:00 3560

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx

ADELAIDE, South Australia, June 3, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced the exclusive rights to utilize CelluTx's Recombination Based Plasmid System (RBPS) technology with BioCina's CDMO clients....

2024-06-03 23:37 3262

Waters Becomes First Liquid Chromatography Column Provider to Receive My Green Lab ACT Ecolabel Certification

News Summary: * Waters becomes the first vendor to obtain ACT™ Ecolabel Certification for 42 of its liquid chromatography columns, providing independent validation of the environmental impact of Waters column manufacturing, use, packaging, and disposal. * Laboratory products that earn the AC...

2024-06-03 20:00 2827

HistoIndex to Showcase Groundbreaking AI-powered Stain-free Digital Pathology Advances with 8 Accepted Abstracts at EASL Congress 2024

* Company to deliver two oral and six poster presentations, including one TOP poster and one selected for poster tour, further reinforcing its leadership position in MASH digital pathology. * HistoIndex's AI-driven solutions provide unprecedented insights into the direct prediction of patient...

2024-06-03 20:00 3027

Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting

* Results from the phase I part of JSKN003-102 was reported at this ASCO Annual Meeting. * JSKN003 exhibited a favorable tolerability and manageable safety profile in heavily pretreated patients with advanced/metastatic solid tumors and demonstrated encouraging antitumor activity during dose ...

2024-06-03 10:17 2745
1 ... 63646566676869 ... 185